Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. has demonstrated steady growth in its EsoGuard test volumes, achieving a year-over-year increase of 2% in Q3 2025, highlighting a positive trend in demand for its diagnostic products. The company is expanding coverage from various payers, including Medicare, which is expected to drive revenue growth significantly as it commercializes its flagship product. Furthermore, the positive outcome of the MolDX CAC meeting positions Lucid Diagnostics favorably for future engagements, suggesting substantial upside potential and reinforcing a bullish outlook on the company's financial prospects.

Bears say

Lucid Diagnostics Inc. experienced a disappointing performance in Q3 2025, with revenue falling short of consensus estimates and a pro forma net loss of $10.3 million, slightly above expectations. The decline in EsoGuard test volume, with a decrease to 2,756 tests in Q2 from prior quarters, highlights challenges in product adoption and market penetration. Additionally, various risks, such as potential issues with insurance reimbursement, regulatory approvals, and increasing competition, contribute to a negative outlook for Lucid’s stock in the near term.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.